CAS: 158681-13-1; Rimonabant Hydrochloride

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号2213-43-6 1-氨基哌啶 | CAS号168273-05-0 5-(4-chlorophen... | CAS号168273-06-1 利莫纳班 | CAS号6285-05-8 4-氯苯丙酮 | CAS号5446-18-4 2,4-二氯苯肼盐酸盐 | CAS号168273-06-1 利莫纳班

合成工艺路线路线简述

    4-氯苯丙酮置于草酰氯,对甲苯磺酸,三乙胺,碘甲烷体系中,用 四氢呋喃,二氯甲烷,N,N-二甲基甲酰胺,甲苯,乙腈 用作溶剂,化学反应 56.0H,反应生成盐酸利莫那班
    参考文献:一种新型实用的盐酸利莫那班合成方法
    标题:一种新型实用的盐酸利莫那班合成方法
    摘要:3 3 的另一种方法是将 1 的烯醇化物(来自 Lihmds)酰化以产生 3.3,4 的锂盐 3 与 2,4-氯苯肼缩合得到苯腙中间体 4,该中间体 4 环化为乙基 5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-羧酸酯(5);5的水解得到5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3羧酸(6),随后将其转化为8(方案1).尽管这种方法似乎是一种可行的方法,因为试剂价格低廉且易于获得,但在我们的实验室中却无法重现.在多次尝试中,结果难以复制,产率波动很大. 3 主要问题是难以去除 1 到 2 转化过程中形成的杂质(和未反应的 1).产物2和原料1的粗混合物的使用导致进一步步骤中的更多杂质.这些粗中间体不容易纯化,因为它们都是油.即使 6 是一种固体并被分离出来,它仍然需要多次重结晶才能得到纯产品.此外,据报道,4的合成也导致苯腙异构体9,因此不可避免地形成副产物10
    Doi:10.1080/00304948.2012.657564

    海关参考信息

    专利信息


    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-8071782-B2
    优先权日:2007-10-02
    标 题 :Synthesis of 1,3,4-trisubstituted and 1,3,4,5-tetrasubstituted pyrazoles
    发明人:DENG XIAOHU; MANI NEELAKANDHA S
    权利人:DENG XIAOHU; MANI NEELAKANDHA S; JANSSEN PHARMACEUTICA NV
    摘要:This invention concerns the synthesis of highly substituted pyrazoles, which are structural components of pharmacological compounds, through reaction of hydrazones with nitroolefins.

    专利号:US-9315483-B2
    优先权日:2007-09-13
    标题 :Synthesis of deuterated catechols and benzo[D][1,3]dioxoles and derivatives thereof
    发明人:JONES ANDREW D; ZELLE ROBERT E; SILVERMAN I ROBERT
    权利人:CONCERT PHARMACEUTICALS INC
    摘要:The present invention provides a convenient and efficient process for the synthesis of d 2 -benzo[d][1,3]dioxoles.

    专利号:US-7955816-B2
    优先权日:2006-05-02
    标 题 :Design and synthesis of biotinylated probes for N-acyl-ethanolamines
    发明人:MACCARRONE MAURO; ODDI SERGIO; FEZZA FILOMENA; FINAZZI AGRO′ ALESSANDRO
    权利人:UNI DEGLI STUDI DI ROMA & LDQUO TOR VERGATA & RDQUO; UNI DEGLI STUDI DI TERAMO
    摘要:The present invention relates to the synthesis and characterization of biotinylated analogue of N-arachidonoylethanolamine (AEA) and its use as a tool to study AEA transport and trafficking through biochemical and morphological techniques. In particular biotinylated AEA (b-AEA, for which we propose the common name MM22) is suitable to design highly sensitive and simple methods for the non-radioactive detection and quantitation of AEA from complex samples, which would offer a useful alternative approach to the routinely used radiometric assays. The invention also relates to the use of b-AEA as a potential therapeutic and diagnostic agent.

    专利号:US-11485700-B2
    优先权日:2018-06-28
    标题:Synthesis of (+)-cannabinoids and their therapeutic effects
    发明人:FIEBICH BERND; WINKLER MATTHIAS; GÖTZ MARCUS RUDOLF; KOCH OSKAR
    权利人:SYMRISE AG
    摘要:The present invention relates to a method of producing a compound of formula (I) or a salt of a compound of formula (I). The invention also relates to a compound of formula (I) or a salt of a compound of formula (I) for use in a therapeutic method to achieve one or more therapeutic effects as well as for use in the treatment and/or prevention of certain diseases. Furthermore, the invention provides a pharmaceutical composition comprising one or more compound(s) of formula (I) or salt(s) of compound(s) of formula (I).

    专利号:US-2009156465-A1
    优先权日:2005-12-30
    标题:Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
    发明人:SATTIGERI JITENDRA A; AHMED SHAHADAT; ANDAPPAN MURUGAIAH M S; SETHI SACHIN; SHARMA LALIMA; PAL CHANCHAL KUMAR; KANDALKAR SACHIN RAMESH; MAHAJAN DIPAK C; KISHORE KAUSHAL; BHATIA SUMATI; GADHAVE ANIL G; BANSAL VINAY S; DAVIS JOSEPH ALEXANAND
    权利人:SATTIGERI JITENDRA A; AHMED SHAHADAT; ANDAPPAN MURUGAIAH M S; SETHI SACHIN; SHARMA LALIMA; PAL CHANCHAL KUMAR; KANDALKAR SACHIN RAMESH; MAHAJAN DIPAK C; KISHORE KAUSHAL; BHATIA SUMATI; GADHAVE ANIL G; BANSAL VINAY S; DAVIS JOSEPH ALEXANAND
    摘要:The present invention relates to β-amino acid derivatives as dipeptidyl peptidase-IV inhibitors and the processes for the synthesis of the same. This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating diabetes, especially type 2 diabetes, as well as prediabetes, diabetic dyslipidemia, metabolic acidosis, ketosis, satiety disorders, and obesity. These inhibitors can also be used to treat conditions manifested by a variety of metabolic, neurological, anti-inflammatory, and autoimmune disorders like inflammatory disease, multiple sclerosis, rheumatoid arthritis; viral, cancer and gastrointestinal disorders. The compounds of this invention can also be used for treatment of infertility arising due to polycystic ovary syndrome.
    江苏联环药业集团公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.lhpharma.com
    电话: 0514-87814842 87829556👤
    📞江苏联环药业集团公司 ⚠️参考联系方式

    销售电话:0514-87814842 87829556
    邮箱:xsb@lhpharma.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北恒硕精细化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hengshuochem.com
    电话: 027-82200625 82830253 82832071👤
    📞湖北恒硕精细化工有限公司 ⚠️参考联系方式

    销售电话:027-82200625 82830253 82832071
    邮箱:hengshuochem@163.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州海盛医药化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hysenpharma.cn
    电话: 0086-571-88298691👤
    📞杭州海盛医药化工有限公司 ⚠️参考联系方式

    销售电话:0086-571-88298691
    邮箱:sales@hysenpharma.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    广州汉众贸易有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.highzoneg.cn
    电话: 020-82323279 88559879👤
    📞广州汉众贸易有限公司 ⚠️参考联系方式

    销售电话:020-82323279 88559879
    邮箱:gamayj@yahoo.com.cn
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES. Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology. 2015 Aug;40(9):2165-74. doi: 10.1038/npp.2015.59. Epub 2015 Mar 5.
    2: Mahmoud MM, Olszewska T, Liu H, Shore DM, Hurst DP, Reggio PH, Lu D, Kendall DA. (4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)(cyclohexyl)methanone hydrochloride (LDK1229): a new cannabinoid CB1 receptor inverse agonist from the class of benzhydryl piperazine analogs. Mol Pharmacol. 2015 Feb;87(2):197-206. doi: 10.1124/mol.114.095471. Epub 2014 Nov 19.
    3: Elrashidi MY, Ebbert JO. Emerging drugs for the treatment of tobacco dependence: 2014 update. Expert Opin Emerg Drugs. 2014 Jun;19(2):243-60. doi: 10.1517/14728214.2014.899580. Epub 2014 Mar 22. Review. doi: 10.1124/jpet.112.201046. Epub 2013 Feb 20.

    合成参考文献


    参考文献:10.1111/j.1365-2982.2010.01473.x
    摘要:Yüce B, Kemmer M, Qian G, Müller M, Sibaev A, Li Y, Kreis ME, Storr M. Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat. Neurogastroenterol Motil. 2010 Jun;22(6):672–e205. doi: 10.1111/j.1365-2982.2010.01473.x.
    摘要:Tear S, Shah S. Tackling obesity and nicotine dependence. IDrugs. 2005 Dec;8(12):964–5.
    参考文献:10.2165/11592040-000000000-00000
    摘要:Cheung BM. Drug treatment for obesity in the post-sibutramine era. Drug Saf. 2011 Aug 01;34(8):641–50. doi: 10.2165/11592040-000000000-00000.
    参考文献:10.1016/j.neuropharm.2011.06.025
    摘要:Orrú M, Quiroz C, Guitart X, Ferré S. Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum. Neuropharmacology. 2011 Oct;61(5-6):967–74. doi: 10.1016/j.neuropharm.2011.06.025.
    参考文献:10.1016/j.neuint.2011.06.019
    摘要:Bisset KM, Dhopeshwarkar AS, Liao C, Nicholson RA. The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro. Neurochem Int. 2011 Oct;59(5):706–13. doi: 10.1016/j.neuint.2011.06.019.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知